Print Friendly Search Results

Drug and therapy development for triple negative breast cancer

Kendrekar, Pravin, editor.

Drug and therapy development for triple negative breast cancer

Kendrekar, Pravin, editor.

9783527841165

9783527841189

9783527841172

1 online resource (323 p.)

Description based upon print version of record.

Conflict of Interest

Intro -- Title Page -- Contents -- Preface -- Part I History of Breast Cancer -- 1 Early-Stage Diagnosis of Breast Cancer: Amelioration in Approaches -- 1.1 Introduction -- 1.2 Imaging Techniques -- 1.2.1 Mammography (MG) -- 1.2.2 Ultrasonography (US) -- 1.2.3 Magnetic Resonance Imaging (MRI) -- 1.3 Microwave Breast Imaging Methods -- 1.3.1 Microwave Tomography -- 1.3.2 Radio-Based Microwave Imaging -- 1.4 Biomarkers and Biosensors for Breast Cancer Detection -- 1.4.1 Biomarkers -- 1.4.2 Biosensors -- 1.5 Conclusion -- Acknowledgment -- Conflict of Interest -- Authors Contribution

2.4.2 Chromosome Segregation Defect Check by HR Repair -- 2.4.3 Aging, Cell Death, and Senescence -- 2.5 Therapeutic Approach -- 2.6 Conclusion -- Abbreviations -- References -- 3 Recent Advancement of Nanotherapeutics to Treat Breast Cancer -- 3.1 Introduction -- 3.2 Pathophysiology of Breast Cancer -- 3.3 Classification of Breast Cancer -- 3.4 Techniques for Breast Cancer Detection -- 3.5 Current Breast Cancer Therapies -- 3.6 Nanotherapeutics for Breast Cancer Treatment and Metastasis -- 3.6.1 Nanodiamonds (NDs) -- 3.6.2 Intrinsic Toxicity Reduction -- 3.6.3 Diminishing Chemoresistance (CR)

3.6.4 Delivery of Combination Therapeutics Through NDs -- 3.7 Polymer-Based Nanoparticles (PBNPs) -- 3.8 Inorganic Nanoparticles (IONPs) -- 3.9 Hydrogels (HGLs) and Microbubbles (MBs) -- 3.10 Recent Patents of Nanotherapeutics for Breast Cancer Treatment -- 3.11 Clinical Trials of Nanotherapeutics for Breast Cancer -- 3.12 Conclusion and Future Perspectives -- References -- 4 HER Receptor in Breast Cancer -- 4.1 Introduction -- 4.2 Role of HER Receptors in the Human Body -- 4.3 HER2 Receptor in Breast Cancer Progression -- 4.4 Conclusion -- Conflict of Interest -- References

5 Human Endogenous Retroviruses in Triple-Negative Breast Cancer -- 5.1 Introduction -- 5.2 HERVs in Breast Cancer and TNBC -- 5.3 TROJAN lncRNA and TNBC -- 5.4 HERVs and Breast Cancer Treatments -- 5.5 Conclusion -- 5.6 Search Strategy -- References -- Part II Novel Drug Discovery and Development -- 6 Development in Drug Repurposing for the Treatment of Acute Leukemia Complicating Metastatic Breast Cancer -- 6.1 Introduction -- 6.1.1 Acute Leukemia's -- 6.1.2 Mitochondrial cAMP-PKA Signaling -- 6.1.3 Nuclear Compartment -- 6.1.4 Cytosolic Compartment and Plasma Membrane -- 6.2 Conclusion

In Drug and Therapy Development for Triple Negative Breast Cancer, a team of distinguished practitioners delivers an in-depth and authoritative discussion of contemporary methods for treating triple negative breast cancer (TNBC). The editors have included material that covers its molecular causes, initial detection, diagnostic tools, treatment procedures, pharmacology, and new and experimental therapies - including nanotherapeutics and photothermal therapies. As the first comprehensive compilation of modern treatment methods for TNBC, this reference is an unmatched source of information about current and future treatment approaches, including machine learning methods for earlier detection and more accurate diagnosis.

John Wiley and Sons

Breast -- Cancer -- Treatment.

Sein -- Cancer -- Traitement.

Pharmacology.

Oncology.

MEDICAL.

Breast -- Cancer -- Treatment

Electronic books.

Kendrekar, Pravin,

Adimule, Vinayak,

Hurst, Tara,

https://onlinelibrary.wiley.com/doi/book/10.1002/9783527841165